Datapoint: FDA Snubs Biocon’s Avastin Biosimilar

The FDA last week rejected Biocon’s Bevacizumab, a biosimilar to Roche’s blockbuster oncology drug Avastin, according to the Center for Biosimilars. Biocon gave few details on the rejection, but it likely stems from issues following an Aug. 22 manufacturing inspection. Avastin was first approved in 2004 for the treatment of colorectal cancer, an indication for which it currently holds covered or better status for 43% of insured lives under the pharmacy benefit, and 86% under the medical benefit.

SOURCE: MMIT Analytics, as of 2/15/23

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
December 7

Datapoint: North Carolina Begins Medicaid Expansion Rollout

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
December 6

Datapoint: Clover Health to Exit ACO REACH Model

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
December 5

Datapoint: Aetna Will Keep Covering Some Virtual Behavioral Health Services

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today